Symbiotec Pharmalab Adopts Fair Disclosure Code Under SEBI PIT Regulations
Symbiotec Pharmalab Limited has adopted a Code of Fair Disclosure under SEBI PIT Regulations, effective December 15, 2025. The policy ensures timely and transparent disclosure of Unpublished Price Sensitive Information (UPSI) to stakeholders.
This is a standard compliance requirement and does not introduce any new business developments or financial changes that would directly impact the company's operations or stock price.
The announcement is a routine compliance filing regarding the adoption of a fair disclosure code as mandated by SEBI regulations. It does not contain any new financial information or strategic changes that would significantly impact the company's outlook.
Symbiotec Pharmalab Limited has formally adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). This code, framed under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, aims to ensure timely and adequate disclosure of UPSI that could impact the company's securities' price.
The policy emphasizes prompt public disclosure of UPSI as soon as credible information becomes available, uniform dissemination to stock exchanges and the company website, and the handling of market rumors and analyst communications. It also outlines procedures for sharing UPSI on a need-to-know basis for legitimate business purposes.
The Code comes into effect on December 15, 2025. The company has appointed a Chief Investor Relations Officer (CIRO) to oversee the dissemination of information and disclosure of UPSI, reporting to the Chief Financial Officer. Employees are restricted from responding to external inquiries unless authorized by the CIRO or CFO.
A plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.